University of Thessaly (UTH)
Ανάπτυξη μεθόδων ανίχνευσης και κλινική σημασία των αντισωμάτων κατά α-ακτινίνης σε ασθενείς με αυτοάνοσα ηπατικά νοσήματα
Abstract
dc:descriptionAlpha-actinin (α-actinin) is a ubiquitous cytoskeletal protein, which belongs to the superfamily of f-actin (FA) crosslinking proteins. Four isoforms of human α-actinin have already been identified namely, the “muscles” α-actinin-2 and α-actinin-3 and the “non-muscles” α-actinin-1 and α-actinin-4. The precise functions of α-actinin isoforms have been elusive. It seems that α-actinin plays a crucial role in pathogenesis of autoimmune diseases, particularly systemic lupus erythematosus (SLE) and autoimmune hepatitis (AH). Previous studies have shown that combined presence of autoantibodies against FA (AFA) and α-actinin are specific for ΑΗ-type 1 (AH-1) diagnosis.Aim of the study: To assess whether anti-a-actinin antibodies and AFA could be used as indicators of response to treatment and predictors of AH-1 flares in a large cohort of AIH-1 patients.Methods: Seven hundred and sixty-four serial serum samples of 86 consecutive AIH-1 patients, 509 pathological and 110 normal controls were tested for the presence of anti-a-actinin antibodies and AFA by an in-house IgG-specific ELISA and a standardised commercially available ELISA respectively. Patients sera were divided into baseline group (active disease before treatment initiation, n = 86) and then according to treatment response into group A-responders (n = 40 patients), group B-relapsers ⁄ incomplete responders (n = 37 patients) and group C-not-treated (n = 9 patients).Results: Anti-a-actinin and AFA levels were significantly higher at baseline. Double reactivity against a-actinin and AFA was associated with disease activity (OR 4.9; 95% CI: 2.7–9). Anti-a-actinin optical densities (ODs) before treatment decreased significantly at first remission (p< 0.05). Treatment response was associated with anti-a-actinin antibodies negativity before treatment (OR 3.4; 95% CI: 1.3–8.9) and absence of double positivity for anti-a-actinin antibodies and AFA before treatment (OR 3.8; 95% CI: 1.4–10.4). Responders had lower baseline levels of anti-a-actinin than relapsers and/or incomplete responders (p = 0.002). Binary logistic regression revealed lower levels of anti-a-actinin as the only independent predictors of response (p = 0.05).Conclusions: Anti-a-actinin antibodies at baseline appear to predict treatment response and therefore they might be used for monitoring treatment outcome in AH-1.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Oikonomou, Katerina
- Οικονόμου, Κατερίνα
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35211